The global sterile filtration market is projected to reach USD 15.3 billion by 2028 from USD 8.9 billion in 2023, at a CAGR of 11.4% during the forecast period of 2023 to 2028. The growth of this market is majorly driven by the advantages of sterile filters over non-sterile filters. Unlike non-sterile filters, sterile filters are more reliable for the removal of all microorganisms and particles from liquids or gases. In addition, sterile filters minimize the risk of contamination with complete ready-to-use units. Such factors are driving the market growth.
The global market is a consolidated market, with Merck KGaA (Germany), Danaher Corporation (US), Sartorius AG (Germany), Thermo Fisher Scientific Inc. (US), and 3M (US) together accounting for ~60–70% of the global market.
To know about the assumptions considered for the study download the pdf brochure
Merck KGaA (Germany)
Merck KGaA provides solutions for the research, development, and production of pharmaceutical drug therapies. Merck Millipore, the life sciences business of Merck KGaA, is a major player in the sterile filtration market, with its leading product lines, such as Aervent, Durapore, and Millipore Express membranes. With a strong geographic presence, a broad portfolio of sterile filtration products, and continuous expansion in developed and developing regions, the company is expected to grow at a high rate in the sterile filtration market during the forecast period.
Danaher Corporation (US)
Danaher became one of the most prominent players in the sterile filtration market after its acquisition of Pall Corporation. The company has a strong portfolio of sterile filtration solutions, including membranes, syringe filters, and capsules. Danaher Corporation has witnessed a consistent increase in its revenue in the last three financial years. This increase can be attributed to strategic agreements, acquisitions, and expansions. In March 2021, Pall acquired Pall-Austar Lifesciences Limited. This acquisition expanded its manufacturing capacity for single-use technologies in China.
Sartorius AG (Germany)
Sartorius provides an extensive range of sterile filtration products for end users such as biopharmaceutical & pharmaceutical companies, CMOs, and CROs. Significant investment in R&D has enabled the company to launch new products such as Sartolab RF|BT Vacuum Filtration Units for laboratory filtration applications. Further, the company has conducted strategic expansions to maintain a competitive edge. For instance, during the past three years, Sartorius increased its geographic presence across China, the UK, South Korea, the US, Puerto Rico, and France through the establishment and expansion of manufacturing facilities and customer interaction centers to support the significant global demand for filtration products, especially to develop and manufacture COVID-19 therapies and vaccines. With a strong geographic presence and continuous expansions in developed and developing regions, the company is expected to grow in the sterile filtration market at a high rate during the forecast period
Sterile Filtration Market by Product (Cartridge, Capsule Filter), Application (API, Vaccine, Antibody, Media, Formulation & Fill Finish), Membrane (PES, PVDF, PTFE), Pore Size, End User (Pharma & Biotech, F&B, CMO) - Global Forecast to 2028
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE